Hyalart D

Hyalart D is a prescription intra‑articular injectable containing sodium hyaluronate as its active ingredient. It is supplied as a sterile solution intended for viscosupplementation in the European market. The product provides viscoelastic supplementation of synovial fluid to support joint function. Hyalart D is classified as a hyaluronic acid preparation and is used under medical supervision. It is administered by a qualified healthcare professional directly into the affected joint space.

Hyalart D is indicated for the symptomatic management of osteoarthritis in joints where conservative therapies have been insufficient.

- Osteoarthritis of the knee, providing intra‑articular supplementation to improve joint lubrication. - Osteoarthritis of the hip, used when pain persists despite standard analgesics. - Osteoarthritis of the ankle or other peripheral joints, administered to enhance synovial fluid viscosity. - Adjunctive therapy in patients awaiting joint replacement surgery, aiming to delay the procedure.

Adverse reactions to Hyalart D are generally localized to the injection site, though systemic events can occur rarely.

Common: - Transient pain or swelling at the injection site. - Mild warmth or flushing in the treated joint. - Temporary stiffness or reduced range of motion. - Low‑grade fever or malaise within 24 hours.

Serious: - Acute joint infection (septic arthritis) requiring medical intervention. - Allergic hypersensitivity reaction, including rash, urticaria, or anaphylaxis. - Persistent joint effusion or severe inflammation. - Nerve injury or vascular compromise at the injection site.

Before administering Hyalart D, clinicians should evaluate patient history and joint condition to minimize risks.

- Confirm absence of active joint infection or skin lesions over the injection site. - Assess for known hypersensitivity to hyaluronic acid or any component of the formulation. - Use caution in patients with severe knee malalignment or mechanical instability. - Avoid use in patients with uncontrolled coagulopathy or on anticoagulant therapy without appropriate monitoring. - Consider postponing treatment during pregnancy or lactation until safety data are available. - Evaluate renal function in patients with severe systemic disease, as clearance may be altered. - Ensure aseptic technique and proper imaging guidance for accurate intra‑articular placement.

Hyalart D may interact with other agents that affect joint health or infection risk.

Avoid: - Concurrent intra‑articular corticosteroid injections within 2 weeks of Hyalart D administration. - Use with intra‑articular antibiotics or other viscosupplements in the same joint during the same treatment cycle.

Use with caution: - Systemic anticoagulants (e.g., warfarin, direct oral anticoagulants) due to increased bleeding risk at the injection site. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may mask early signs of infection. - Disease‑modifying osteoarthritis drugs (DMOADs) where combined effects on cartilage are not fully established. - Immunosuppressive therapies that could predispose to joint infection.